Giant-Cell Arteritis Pipeline Insight Report 2019 -

DUBLIN--()--The "Giant-Cell Arteritis Pipeline Insight, 2019" drug pipelines has been added to's offering.

Giant-Cell Arteritis (GCA) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Giant-Cell Arteritis (GCA) pipeline landscape is provided which includes the disease overview and Giant-Cell Arteritis treatment guidelines.

The assessment part of the report embraces, in depth Giant-Cell Arteritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Giant-Cell Arteritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Giant-Cell Arteritis (GCA) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Giant-Cell Arteritis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Giant-Cell Arteritis pipeline report covers 6+ companies. Some of the key players include Regeneron/Sanofi (Sarilumab), AbbVie (Upadacitinib), Novartis (Secukinumab) etc.

Giant-Cell Arteritis (GCA) Analytical Perspective

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Key Topics Covered:

1. Report Introduction

2. Giant-Cell Arteritis (GCA) (Temporal arteritis; Cranial Arteritis; Granulomatous Arteritis and Horton's disease)

2.1. Giant-Cell Arteritis (GCA) Disease Overview

2.2. Giant-Cell Arteritis (GCA) History

2.3. Giant-Cell Arteritis (GCA) Symptoms

2.4. Giant-Cell Arteritis (GCA) Causes

2.5. Giant-Cell Arteritis (GCA) Pathophysiology

2.6. Giant-Cell Arteritis (GCA) Diagnosis

3. Giant-Cell Arteritis (GCA) Current Treatment Patterns

3.1. Treatment Guidelines

4. Giant-Cell Arteritis (GCA) - Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Giant-Cell Arteritis companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Giant-Cell Arteritis Collaboration Deals Company-Company Collaborations (Licensing/Partnering) Analysis Giant-Cell Arteritis Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination) Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Giant-Cell Arteritis Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Giant-Cell Arteritis - Products Analysis

6.1. Product Profiles

6.1.1. Sarilumab - Regeneron/Sanofi

6.1.2. Upadacitinib - AbbVie

6.1.3. Secukinumab - Novartis

7. Recent Technologies

8. Giant-Cell Arteritis Key Companies

8.1. AbbVie

8.2. Novartis

8.3. Incyte Corporation

8.4. Regeneron/Sanofi

8.5. Kiniksa Pharmaceuticals

8.6. Janssen Biotech

9. Giant-Cell Arteritis Key Products

9.1. Upadacitinib

9.2. Secukinumab

9.3. Baricitinib

9.4. Sarilumab

9.5. Mavrilimumab

9.6. Sirukumab

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Giant-Cell Arteritis - Unmet Needs

12. Giant-Cell Arteritis - Future Perspectives

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900